Zambon与Amneal宣布Hopledo® (ipx203)获欧盟CHMP正面评价，用于治疗帕金森病伴中重度运动波动成人患者

美股速递06-29

Zambon公司与Amneal Pharmaceuticals, Inc.联合宣布，其合作研发的药物Hopledo® (ipx203)已获得欧洲药品管理局人用药品委员会（CHMP）的正面评价。该药物适用于治疗患有帕金森病并伴随中度至重度运动波动的成人患者。

此次CHMP的积极意见是基于关键性临床试验的有利数据，表明ipx203在控制运动症状波动方面具有潜在疗效。若后续获得欧盟委员会正式批准，该疗法将为帕金森病患者提供一种新的治疗选择。

运动波动是帕金森病进展过程中常见的并发症，可能导致患者在日常活动中经历不可预测的运动功能变化。新药的研发进展有望帮助改善这类患者的生活质量与症状管理。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1107089082?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-29 15:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107089082","market":"us","top_or_hot":-1,"title":"Zambon与Amneal宣布Hopledo® (ipx203)获欧盟CHMP正面评价，用于治疗帕金森病伴中重度运动波动成人患者","media":"美股速递","content":"<p>Zambon公司与Amneal Pharmaceuticals, Inc.联合宣布，其合作研发的药物Hopledo® (ipx203)已获得欧洲药品管理局人用药品委员会（CHMP）的正面评价。该药物适用于治疗患有帕金森病并伴随中度至重度运动波动的成人患者。</p>\n<p>此次CHMP的积极意见是基于关键性临床试验的有利数据，表明ipx203在控制运动症状波动方面具有潜在疗效。若后续获得欧盟委员会正式批准，该疗法将为帕金森病患者提供一种新的治疗选择。</p>\n<p>运动波动是帕金森病进展过程中常见的并发症，可能导致患者在日常活动中经历不可预测的运动功能变化。新药的研发进展有望帮助改善这类患者的生活质量与症状管理。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zambon与Amneal宣布Hopledo® (ipx203)获欧盟CHMP正面评价，用于治疗帕金森病伴中重度运动波动成人患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZambon与Amneal宣布Hopledo® (ipx203)获欧盟CHMP正面评价，用于治疗帕金森病伴中重度运动波动成人患者\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-29 15:03 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zambon公司与Amneal Pharmaceuticals, Inc.联合宣布，其合作研发的药物Hopledo® (ipx203)已获得欧洲药品管理局人用药品委员会（CHMP）的正面评价。该药物适用于治疗患有帕金森病并伴随中度至重度运动波动的成人患者。\n此次CHMP的积极意见是基于关键性临床试验的有利数据，表明ipx203在控制运动症状波动方面具有潜在疗效。若后续获得欧盟委员会正式批准，该疗法...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1107089082","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107089082","pubTimestamp":1782716600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zambon公司与Amneal Pharmaceuticals, Inc.联合宣布，其合作研发的药物Hopledo® (ipx203)已获得欧洲药品管理局人用药品委员会（CHMP）的正面评价。该药物适用于治疗患有帕金森病并伴随中度至重度运动波动的成人患者。\n此次CHMP的积极意见是基于关键性临床试验的有利数据，表明ipx203在控制运动症状波动方面具有潜在疗效。若后续获得欧盟委员会正式批准，该疗法将为帕金森病患者提供一种新的治疗选择。\n运动波动是帕金森病进展过程中常见的并发症，可能导致患者在日常活动中经历不可预测的运动功能变化。新药的研发进展有望帮助改善这类患者的生活质量与症状管理。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Zambon, Amneal Announce Hopledo ® (ipx203) was positively evaluated by the EU CHMP for the treatment of adult patients with Parkinson's disease with moderate to severe movement fluctuations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Zambon公司与Amneal Pharmaceuticals, Inc.联合宣布，其合作研发的药物Hopledo® (ipx203)已获得欧洲药品管理局人用药品委员会（CHMP）的正面评价。该药物适用于治疗患有帕金森病并伴随中度至重度运动波动的成人患者。\n此次CHMP的积极意见是基于关键性临床试验的有利数据，表明ipx203在控制运动症状波动方面具有潜在疗效。若后续获得欧盟委员会正式批准，该疗法将为帕金森病患者提供一种新的治疗选择。\n运动波动是帕金森病进展过程中常见的并发症，可能导致患者在日常活动中经历不可预测的运动功能变化。新药的研发进展有望帮助改善这类患者的生活质量与症状管理。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107089082","isCrawlerRequest":true}